Pub Date : 1900-01-01DOI: 10.25179/tjem.2021-83124
M. Hemmatabadi, Nasrin Asgari- -SORAN, F. Esfahanian, Elham Sharafi, M. Qorbani, Nooshin Shirza
*Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, IRAN **Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, IRAN ***Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, IRAN ****Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, IRAN Original Article Turk J Endocrinol Metab. 2021;25:288-294
{"title":"Comparison of Mental Health and Quality of Life in Euthyroid Patients Under Levothyroxine Mono-therapy Based on the Causes of Hypothyroidism","authors":"M. Hemmatabadi, Nasrin Asgari- -SORAN, F. Esfahanian, Elham Sharafi, M. Qorbani, Nooshin Shirza","doi":"10.25179/tjem.2021-83124","DOIUrl":"https://doi.org/10.25179/tjem.2021-83124","url":null,"abstract":"*Department of Endocrinology, Vali-Asr Hospital, Endocrinology and Metabolism Research Center, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, IRAN **Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, IRAN ***Department of Psychiatry, Psychosomatic Research Center, Tehran University of Medical Sciences, Tehran, IRAN ****Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, IRAN Original Article Turk J Endocrinol Metab. 2021;25:288-294","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133764548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2021-86803
F. Bayram, T. Bayraktaroğlu, M. Sargin, I. Sahin, Sibel Güldiken, Ayşegül Dalbeler, A. Sönmez
Division of Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, TURKIYE *Division of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Obesity and Diabetes Application and Research Center, Zonguldak, TURKIYE **Department of Family Medicine, İstanbul Medeniyet University Faculty of Medicine, İstanbul, TURKIYE ***Division of Endocrinology and Metabolism, İnönü University Faculty of Medicine, Malatya, TURKIYE ****Division of Endocrinology and Metabolism, Trakya University Faculty of Medicine, Edirne, TURKIYE *****Medical and Scientific Affairs Department/CMRQ, Novo Nordisk Health Products Tic. Ltd. Şti., İstanbul, TURKIYE ******Division of Endocrinology and Metabolism, University of Health Sciences Gülhane Faculty of Medicine, Ankara, TURKIYE Original Research
土耳其开塞利埃尔西耶斯大学医学院内分泌与代谢学部*土耳其宗乌尔达克大学肥胖与糖尿病应用研究中心内分泌与代谢学部** İstanbul梅迪尼耶特大学医学院家庭医学系İstanbul土耳其宗乌尔耶斯*** İnönü土耳其马拉提亚大学医学院内分泌与代谢学部****内分泌与代谢学部土耳其埃迪尔内特拉基亚大学医学院*****医疗科学事务部/诺和诺德健康产品中心CMRQŞti。， İstanbul, TURKIYE ******安卡拉健康科学大学尔哈内医学院内分泌与代谢学系，土耳其
{"title":"A Cross-Sectional Study of the Prevalence of Cardiovascular Disease in Adults with Type 2 Diabetes in Türkiye: The CAPTURE Study","authors":"F. Bayram, T. Bayraktaroğlu, M. Sargin, I. Sahin, Sibel Güldiken, Ayşegül Dalbeler, A. Sönmez","doi":"10.25179/tjem.2021-86803","DOIUrl":"https://doi.org/10.25179/tjem.2021-86803","url":null,"abstract":"Division of Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, TURKIYE *Division of Endocrinology and Metabolism, Zonguldak Bülent Ecevit University Obesity and Diabetes Application and Research Center, Zonguldak, TURKIYE **Department of Family Medicine, İstanbul Medeniyet University Faculty of Medicine, İstanbul, TURKIYE ***Division of Endocrinology and Metabolism, İnönü University Faculty of Medicine, Malatya, TURKIYE ****Division of Endocrinology and Metabolism, Trakya University Faculty of Medicine, Edirne, TURKIYE *****Medical and Scientific Affairs Department/CMRQ, Novo Nordisk Health Products Tic. Ltd. Şti., İstanbul, TURKIYE ******Division of Endocrinology and Metabolism, University of Health Sciences Gülhane Faculty of Medicine, Ankara, TURKIYE Original Research","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133906862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-66818
P. Şişman, B. Bicer, H. Oztop, S. Cander, O. O. Gul, G. Ocakoglu, C. Ersoy, E. Ertürk
{"title":"Demographic and Clinical Features of Medullary Thyroid Carcinoma","authors":"P. Şişman, B. Bicer, H. Oztop, S. Cander, O. O. Gul, G. Ocakoglu, C. Ersoy, E. Ertürk","doi":"10.25179/tjem.2019-66818","DOIUrl":"https://doi.org/10.25179/tjem.2019-66818","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133012826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/TJEM.2020-77446
Mohammad Hayat Bhat, J. Bhat, S. Masoodi, W. Qureshi, Junaid Rashid Dar, M. Bhat
Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treatment outcome of GD in the post-iodization scenario. Material and Methods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 males and 53 females) attending our center were reviewed retrospectively. The demographic data, modes of treatment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with anti-thyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagnosis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/or goiter, although the atypical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remission. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On follow-up at three months, 46.1% of the patients were euthyroid, with normalization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical therapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly associated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accurate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.
目的:Graves病(GD)是一种常见的自身免疫性疾病，预后多变。我们的目的是研究碘化后GD的临床表现和治疗结果。材料与方法:本研究设计为横断面研究，回顾性分析本中心共180例GD患者(男性127例，女性53例)。确定患者的人口统计数据、治疗方式、合并症、缓解和复发率。所有患者最初均使用抗甲状腺药物(ATDs)治疗，随后根据病程进行治疗。结果:诊断时的平均(±SD)年龄为38.30(10.73)岁，从症状出现到诊断的滞后时间为5.12(2.69)个月，男性患者病程明显短于女性(4.36 vs. 5.44个月;P = 0.015)。大多数患者表现出与甲状腺功能亢进和/或甲状腺肿相关的典型症状和体征，尽管非典型表现并不罕见。ATDs是实现临床和生化缓解的首选治疗方式。达到甲亢的平均时间为3.31±1.51个月，TSH水平恢复正常的平均时间为7.45±3.35个月。随访3个月，46.1%的患者甲状腺功能正常，15.6%的患者TSH水平恢复正常。在男性(p=0.003)和吸烟者(p=0.036)中，未能实现早期缓解/疾病控制的比例明显更高。在完成药物治疗的72例患者中，49例患者缓解，其中20例复发，第一年复发率为20.4%。疾病复发与首发时较高的99 mtc (99mTc)摄取(p=0.022)和较高程度的甲状腺肿(p=0.026)显著相关。logistic回归分析显示男性(p=0.048)和眼病(p=0.036)是预测GD复发的独立危险因素。结论:Graves病临床表现多样，有不典型的临床表现，应仔细临床评估，以确保准确诊断。性别和眼病是预测疾病复发的独立危险因素。
{"title":"Clinical Spectrum and Outcome of Patients with Graves’ Disease: A Single-Center Experience from a Tertiary Care Institution in the Kashmir Valley, India","authors":"Mohammad Hayat Bhat, J. Bhat, S. Masoodi, W. Qureshi, Junaid Rashid Dar, M. Bhat","doi":"10.25179/TJEM.2020-77446","DOIUrl":"https://doi.org/10.25179/TJEM.2020-77446","url":null,"abstract":"Objective: Graves’ disease (GD) is a common autoimmune disorder with variable outcomes. We aim to study the clinical manifestations and treatment outcome of GD in the post-iodization scenario. Material and Methods: The present study was designed as a cross-sectional study, in which a total of 180 patients with GD (127 males and 53 females) attending our center were reviewed retrospectively. The demographic data, modes of treatment, comorbidities, remission, and recurrence rates were determined for the patients. All patients were initially treated with anti-thyroid drugs (ATDs), with the subsequent management depending on the course of the disease. Results: The mean (±SD) age at diagnosis was 38.30 (10.73) years and the lag period between the onset of symptoms and the diagnosis was 5.12 (2.69) months, with the male patients having a significantly shorter duration of illness compared to females (4.36 vs. 5.44 months; P=0.015). Majority of the patients presented with the typical symptoms and signs associated with hyperthyroidism and/or goiter, although the atypical presentations were not uncommon. ATDs were the most preferred treatment modality employed to achieve clinical and biochemical remission. The mean duration of achieving euthyroidism and the normalization of TSH levels were 3.31±1.51 and 7.45±3.35 months, respectively. On follow-up at three months, 46.1% of the patients were euthyroid, with normalization of the TSH levels in 15.6% of them. Failure to achieve early remission/disease control was significantly higher in males (p=0.003) and smokers (p=0.036). Among the 72 patients who completed medical therapy, 49 patients achieved remission, of whom 20 patients relapsed with a first-year relapse rate of 20.4%. Disease relapse was significantly associated with higher initial 99 mTechnetium (99mTc) uptake (p=0.022) and higher grade of goiter (p=0.026) at presentation. The logistic regression analysis revealed male gender (p=0.048) and orbitopathy (p=0.036) as the independent risk factors predicting relapse of the GD. Conclusion: Graves’ disease manifests with varied clinical manifestations, including the atypical ones, warranting careful clinical assessment to ensure an accurate diagnosis. Gender and orbitopathy are the independent risk factors predicting the relapse of the disease.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"84 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115874586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2018-62733
T. Telli, M. Tuncel, S. Kılıçkap
D O I: 10 .2 51 79 /t je m .2 01 862 73 3 A 70-year-old female with the diagnosis of the metastatic neuroendocrine tumor was referred to our clinic with new abdominal lymph nodes in computed tomography (CT). This finding was considered as the disease progression, and Capecitabine along with Temozolomide was added to her current Lanreotide therapy. The origin of the new lymph nodes was uncertain due to no response to chemotherapy and the stability of the lymph nodes. 68Ga-DOTATATE PET-CT was performed to resolve the inconsistency in clinical and imaging findings. PET-CT images showed high 68GaDOTATATE uptake in abdominal, cervical, left supraclavicular lymph nodes, and few metastatic foci in the liver, which were compatible with a neuroendocrine tumor. Additionally, there were bilaterally enlarged lymph nodes in the neck, axillary, intra-abdominal and inguinal area with no tracer uptake. The incongruent findings of PET-CT suggested a biopsy of non-radio-avid lymph nodes for the possible exclusion of other etiologies. Biopsy revealed that the enlargement of the lymph nodes was caused by small lymphocytic lymphoma (SLL) rather than neuroendocrine metastases. 68GaDOTATATE PET-CT led to a critical change in the disease management and confirmed the diagnosis of the secondary tumor with the aid of biopsy. A high radiotracer uptake of neuroendocrine metastases on Ga-68 DOTATATE PET-CT suggested to change the chemotherapy (Capecitabine + Temozolomide) to Y-90/Lu-177 DOTATATE therapy, which led to disease stabilization and minor regression. Her newly diagnosed stable SLL was followed accordingly. It can be concluded that 68Ga-DOTATATE PET-CT plays a critical role in the management of patients with neuroendocrine tumors and should be used as a problem solving tool in patients with the discrepancy between clinical and imaging findings.
{"title":"Critical Role of Ga–68 DOTATATE PET-CT in a Patient with Neuroendocrine Tumor and Second Primary Cancer","authors":"T. Telli, M. Tuncel, S. Kılıçkap","doi":"10.25179/tjem.2018-62733","DOIUrl":"https://doi.org/10.25179/tjem.2018-62733","url":null,"abstract":"D O I: 10 .2 51 79 /t je m .2 01 862 73 3 A 70-year-old female with the diagnosis of the metastatic neuroendocrine tumor was referred to our clinic with new abdominal lymph nodes in computed tomography (CT). This finding was considered as the disease progression, and Capecitabine along with Temozolomide was added to her current Lanreotide therapy. The origin of the new lymph nodes was uncertain due to no response to chemotherapy and the stability of the lymph nodes. 68Ga-DOTATATE PET-CT was performed to resolve the inconsistency in clinical and imaging findings. PET-CT images showed high 68GaDOTATATE uptake in abdominal, cervical, left supraclavicular lymph nodes, and few metastatic foci in the liver, which were compatible with a neuroendocrine tumor. Additionally, there were bilaterally enlarged lymph nodes in the neck, axillary, intra-abdominal and inguinal area with no tracer uptake. The incongruent findings of PET-CT suggested a biopsy of non-radio-avid lymph nodes for the possible exclusion of other etiologies. Biopsy revealed that the enlargement of the lymph nodes was caused by small lymphocytic lymphoma (SLL) rather than neuroendocrine metastases. 68GaDOTATATE PET-CT led to a critical change in the disease management and confirmed the diagnosis of the secondary tumor with the aid of biopsy. A high radiotracer uptake of neuroendocrine metastases on Ga-68 DOTATATE PET-CT suggested to change the chemotherapy (Capecitabine + Temozolomide) to Y-90/Lu-177 DOTATATE therapy, which led to disease stabilization and minor regression. Her newly diagnosed stable SLL was followed accordingly. It can be concluded that 68Ga-DOTATATE PET-CT plays a critical role in the management of patients with neuroendocrine tumors and should be used as a problem solving tool in patients with the discrepancy between clinical and imaging findings.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131019267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/TJEM.2018-63282
Bilal Natiq Nuaman, Asaad M M Sadik
{"title":"Migraine is Strongly Associated with Central Obesity Than with General Obesity: A Case-Control Study","authors":"Bilal Natiq Nuaman, Asaad M M Sadik","doi":"10.25179/TJEM.2018-63282","DOIUrl":"https://doi.org/10.25179/TJEM.2018-63282","url":null,"abstract":"","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126676295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2018-64415
D. Karamanlioğlu, M. Kaysin, Naciye Bilgin Badur, F. Ozkan, I. Aktas
Introduction Typical characteristics of osteoporosis include low bone mass with microarchitectural disruption and skeletal fragility, with increased risk of vertebral and nonvertebral fracture (1). Bisphosphonates suppress osteoclast activity, resulting in the inhibition of bone resorption. The beneficial effects of bisphosphonates on prevention of vertebral and nonvertebral osteoporotic fractures and increase in bone mineral density have been substantiated by several clinical trial data (2-4). Despite the beneficial effects of bisphosphonates, a meta-analysis of six cohorts and five case-control studies reported an increased risk of atypical fracture in bisphosphonate users (5). Vitamin D deficiency is a co-determinant causing fractures, which is a common issue, especially in the elderly population. Clinical studies indicate an association between vitamin D deficiency, osteoporosis, and increased risk of fractures due to falls (6-9). We present here the case of a 79-year-old woman who has been on bisphosphonate treatment for eight years (alendronate for five years, ibandronate for three years). She had bilateral femur diaphyseal fractures occurring within an interval of few months. Laboratory results indicated vitamin D deficiency. We also attempted to investigate the association of atypical femur fractures with the long-term use of bisphosphonate and with vitamin D deficiency.
{"title":"Bilateral Atypical Femur Fracture in a Patient Under Bisphosphonate Treatment","authors":"D. Karamanlioğlu, M. Kaysin, Naciye Bilgin Badur, F. Ozkan, I. Aktas","doi":"10.25179/tjem.2018-64415","DOIUrl":"https://doi.org/10.25179/tjem.2018-64415","url":null,"abstract":"Introduction Typical characteristics of osteoporosis include low bone mass with microarchitectural disruption and skeletal fragility, with increased risk of vertebral and nonvertebral fracture (1). Bisphosphonates suppress osteoclast activity, resulting in the inhibition of bone resorption. The beneficial effects of bisphosphonates on prevention of vertebral and nonvertebral osteoporotic fractures and increase in bone mineral density have been substantiated by several clinical trial data (2-4). Despite the beneficial effects of bisphosphonates, a meta-analysis of six cohorts and five case-control studies reported an increased risk of atypical fracture in bisphosphonate users (5). Vitamin D deficiency is a co-determinant causing fractures, which is a common issue, especially in the elderly population. Clinical studies indicate an association between vitamin D deficiency, osteoporosis, and increased risk of fractures due to falls (6-9). We present here the case of a 79-year-old woman who has been on bisphosphonate treatment for eight years (alendronate for five years, ibandronate for three years). She had bilateral femur diaphyseal fractures occurring within an interval of few months. Laboratory results indicated vitamin D deficiency. We also attempted to investigate the association of atypical femur fractures with the long-term use of bisphosphonate and with vitamin D deficiency.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117321847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/TJEM.2019-65964
M. Kocabaş, M. Karakose, M. Can, H. Ataseven, İ. Çordan, M. Kulaksızoğlu, F. Karakurt
®Copyright 2019 by Turkish Journal of Endocrinology and Metabolism Association Turkish Journal of Endocrinology and Metabolism published by Türkiye Klinikleri Insulin Washout in Fine-Needle Aspiration Fluid for Preoperative Diagnosis of Suspicious Lesion in Patients with Insulinoma: A Case Report İnsülinoma Hastalarında Şüpheli Lezyonun Preoperatif Tanısı İçin İnce İğne Aspirasyon Sıvısında İnsülin Yıkama: Bir Olgu Sunumu
{"title":"Insulin Washout in Fine-Needle Aspiration Fluid for Preoperative Diagnosis of Suspicious Lesion in Patients with Insulinoma: A Case Report","authors":"M. Kocabaş, M. Karakose, M. Can, H. Ataseven, İ. Çordan, M. Kulaksızoğlu, F. Karakurt","doi":"10.25179/TJEM.2019-65964","DOIUrl":"https://doi.org/10.25179/TJEM.2019-65964","url":null,"abstract":"®Copyright 2019 by Turkish Journal of Endocrinology and Metabolism Association Turkish Journal of Endocrinology and Metabolism published by Türkiye Klinikleri Insulin Washout in Fine-Needle Aspiration Fluid for Preoperative Diagnosis of Suspicious Lesion in Patients with Insulinoma: A Case Report İnsülinoma Hastalarında Şüpheli Lezyonun Preoperatif Tanısı İçin İnce İğne Aspirasyon Sıvısında İnsülin Yıkama: Bir Olgu Sunumu","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"2016 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123631492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2021-85359
U. Soyaltin, G. Özgen, T. Kabalak
Introduction Thyroid hormone and adenosine monophosphate-activated protein kinase (AMPK) are 2 major determinants of energy balance. Thyroid hormone is known to be a key factor that stimulates energy use in energy balance. It is involved in almost every stage of energy use. The uptake of energy substances into the cell, their conversion to adenosine triphosphate (ATP) in the mitochondria, and the use of ATP in all cellular processes where energy is required are under the stimulating control of tri-iodothyronine and partially 3,5-diiodo-L-thyronine. A deficiency in thyroid hormone production results in ineffective utilization of energy substrates in the cell, despite their sufficient level. A well-known example of this condiAn increase in the adenosine monophosphate (AMP)/adenosine triphosphate ratio activates AMP-activated protein kinase (AMPK), leading to inhibition of the mammalian target of rapamycin signaling pathway that is associated with autophagy, mitochondriogenesis, glucose uptake, mRNA stabilization, and cell cycle regulation. Metformin activates AMPK and inhibits mitochondrial oxidative phosphorylation. Currently, there is an increasing interest in investigating the effects of metformin on thyroid diseases. Recent data show an association between metformin treatment and lower incidence of thyroid cancer, better survival of patients with thyroid cancer, and lower thyroid volume and nodule size. Insulin-like growth factor receptor and AKT pathways are the AMPK-independent mechanisms through which metformin acts on thyroid diseases. Although metformin has a promising role in adjuvant therapy for thyroid cancers, welldesigned prospective trials are required before reaching a final decision.
甲状腺激素和腺苷单磷酸活化蛋白激酶(AMPK)是能量平衡的两个主要决定因素。众所周知，甲状腺激素是促进能量平衡中能量使用的关键因素。它几乎涉及能源使用的每个阶段。能量物质进入细胞，在线粒体中转化为三磷酸腺苷(ATP)，以及ATP在所有需要能量的细胞过程中的使用都受到三碘甲状腺原氨酸和部分3,5-二碘- l -甲状腺原氨酸的刺激控制。甲状腺激素的缺乏导致细胞内能量底物的无效利用，尽管它们的水平足够。一个众所周知的例子是，单磷酸腺苷(AMP)/三磷酸腺苷比例的增加激活了AMP活化的蛋白激酶(AMPK)，从而抑制了雷帕霉素信号通路的哺乳动物靶点，该信号通路与自噬、线粒体形成、葡萄糖摄取、mRNA稳定和细胞周期调节有关。二甲双胍激活AMPK并抑制线粒体氧化磷酸化。目前，人们对二甲双胍对甲状腺疾病的影响越来越感兴趣。最近的数据显示，二甲双胍治疗与较低的甲状腺癌发病率、较好的甲状腺癌患者生存率以及较小的甲状腺体积和结节大小之间存在关联。胰岛素样生长因子受体和AKT通路是二甲双胍作用于甲状腺疾病的不依赖ampk的机制。虽然二甲双胍在甲状腺癌的辅助治疗中有很好的作用，但在做出最终决定之前，需要精心设计的前瞻性试验。
{"title":"Thyroid Diseases, Metformin and the AMP Kinase Pathway","authors":"U. Soyaltin, G. Özgen, T. Kabalak","doi":"10.25179/tjem.2021-85359","DOIUrl":"https://doi.org/10.25179/tjem.2021-85359","url":null,"abstract":"Introduction Thyroid hormone and adenosine monophosphate-activated protein kinase (AMPK) are 2 major determinants of energy balance. Thyroid hormone is known to be a key factor that stimulates energy use in energy balance. It is involved in almost every stage of energy use. The uptake of energy substances into the cell, their conversion to adenosine triphosphate (ATP) in the mitochondria, and the use of ATP in all cellular processes where energy is required are under the stimulating control of tri-iodothyronine and partially 3,5-diiodo-L-thyronine. A deficiency in thyroid hormone production results in ineffective utilization of energy substrates in the cell, despite their sufficient level. A well-known example of this condiAn increase in the adenosine monophosphate (AMP)/adenosine triphosphate ratio activates AMP-activated protein kinase (AMPK), leading to inhibition of the mammalian target of rapamycin signaling pathway that is associated with autophagy, mitochondriogenesis, glucose uptake, mRNA stabilization, and cell cycle regulation. Metformin activates AMPK and inhibits mitochondrial oxidative phosphorylation. Currently, there is an increasing interest in investigating the effects of metformin on thyroid diseases. Recent data show an association between metformin treatment and lower incidence of thyroid cancer, better survival of patients with thyroid cancer, and lower thyroid volume and nodule size. Insulin-like growth factor receptor and AKT pathways are the AMPK-independent mechanisms through which metformin acts on thyroid diseases. Although metformin has a promising role in adjuvant therapy for thyroid cancers, welldesigned prospective trials are required before reaching a final decision.","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134115081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.25179/tjem.2019-65572
Hanan L. Al-Omary, Zainab M. Alawad, B. Husseini
I. Thehistoryof cell-freeDNA(cfDNA)discovery Cell-free DNA (cfDNA) was discovered in 1948 by Mandel and Mëtais, who observed the existence of free nucleic acids in plasma (1). They found free DNA and RNA in the plasma of healthy as well as unhealthy people. In 1965, Bendich et al. suggested that cfDNA from cancer tissue could be involved in cancer metastasis. In 1966, Tan et al. found an enormous amount of cfDNA in the blood of patients with systemic lupus erythematosus (2). Technological limitations delayed the confirmation of use of cfDNA as an indicator of diseases. Figure 1 shows the presence of cfDNA in blood (3). II. Definition of cfDNA cfDNA means DNA fragments present outside the nucleus of a cell. cfDNA is mainly produced by an apoptotic or necrotic process. The fragments are also present in body fluids, so they can be considered as biological markers of pathological states (4). cfDNA has also been discovered in human seminal fluid (5).
{"title":"Cell-free DNA as a Clinical Indicator in Maternal Blood","authors":"Hanan L. Al-Omary, Zainab M. Alawad, B. Husseini","doi":"10.25179/tjem.2019-65572","DOIUrl":"https://doi.org/10.25179/tjem.2019-65572","url":null,"abstract":"I. Thehistoryof cell-freeDNA(cfDNA)discovery Cell-free DNA (cfDNA) was discovered in 1948 by Mandel and Mëtais, who observed the existence of free nucleic acids in plasma (1). They found free DNA and RNA in the plasma of healthy as well as unhealthy people. In 1965, Bendich et al. suggested that cfDNA from cancer tissue could be involved in cancer metastasis. In 1966, Tan et al. found an enormous amount of cfDNA in the blood of patients with systemic lupus erythematosus (2). Technological limitations delayed the confirmation of use of cfDNA as an indicator of diseases. Figure 1 shows the presence of cfDNA in blood (3). II. Definition of cfDNA cfDNA means DNA fragments present outside the nucleus of a cell. cfDNA is mainly produced by an apoptotic or necrotic process. The fragments are also present in body fluids, so they can be considered as biological markers of pathological states (4). cfDNA has also been discovered in human seminal fluid (5).","PeriodicalId":425605,"journal":{"name":"The Turkish Journal of Endocrinology and Metabolism","volume":"57 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132360584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：